In breast cancer patients, menstrual recovery was 70.0% with goserelin versus 56.7% without it (difference 13.3%; 95% CI, -10.85 to 37.45; P = .284).
In plain wordsIn breast cancer patients, menstrual recovery did not differ significantly between chemotherapy with and without goserelin.
- Peptide
- Goserelin
- Outcome
- No significant changeReappearance of menstruation at 6 months
- Study
n = 60
- Comparator
- Chemotherapy without goserelin
- Analysis
- Primary
- Outcome group
- Sex hormones and fertility · Reproductive and sexual health
- Studied dose
- 3.6 mg every 4 weeks · subcutaneous · Until the end of the last chemotherapy cycleAs given in this study (human).
Measurements
- Reappearance of menstruation at 6 months
- 70%
- With goserelin
- Reappearance of menstruation at 6 months
- 56.7%
- Without goserelin
- Difference in reappearance of menstruation
- 13.3%
- 95% CI -10.85 to 37.45
Source sentences
No significant difference was observed regarding the reappearance of menstruation at 6 months after chemotherapy (70.0% with v 56.7% without goserelin; difference of 13.3%; 95% CI, -10.85 to 37.45; P = .284).
3 context sentences(design, population, supporting numbers)
In a prospective, randomized, open-label, controlled multicenter study, 60 patients younger than age 46 years with hormone-insensitive breast cancer were allocated to receive anthracycline/cyclophosphamide (with or without taxane) -based neoadjuvant chemotherapy with or without goserelin.
The first goserelin injection was administered at least 2 weeks before the first chemotherapy cycle, continuing at 3.6 mg subcutaneously every 4 weeks until the end of the last cycle.
The primary objective was the reappearance of normal ovarian function, defined as two consecutive menstrual periods within 21 to 35 days at 6 months after end of chemotherapy.